Asbestos Mesothelioma – Gender, Can It Be The Next Hope For Cancer?

Europe and the United States probably have a year left after graduating from gene therapy. However, at least two clinical trials are currently undergoing gene therapy for mesothelioma. These include the University of Pennsylvania and Louisiana State University. Unfortunately, gene therapy research took a major hit when teenager Jesse Gelsinger died in 1999 at a genealogy therapy clinical trial at the University of Pennsylvania.

However, China is already the only country in the world that has approved gene therapy. On October 16, 2003, a drug called Gendicine was approved by the State Food and Drug Administration. Gender was more than 5 years old before clinical trials were approved. Currently, this therapy has been used in more than 4500 patients and has been followed for patients over 6 years. Now, hundreds of cancer patients around the world are traveling to Beijing to receive this cutting-edge treatment.

Gendicine's clinical trials included 135 patients, and according to the results, 64% of patients showed tumor regression with 8 weeks of radiation therapy. Depending on the results of the clinical trial, the use of Gendicine with chemotherapy and radiotherapy may improve efficacy 3-fold. The only side effect of gendik is night fever.

With no other gene therapy approved in the world, many cancer patients from North America and Europe are traveling to Beijing (China) to receive Gendicine treatment.

Richard Weissenborn of Texas, spread to lymph nodes that had cancer of the tongue and spent two months living in July 2006. Dr. Li Dinggang was treated by Gendikina and Chemotherapy at Haidan Hospital in Beijing. US $ 30,000

Two months after two treatment cycles, a pet was shown to have a pet-related illness. The controversy surrounding the story is: Richard & # 39; although cancer has disappeared, there is some doubt that chemotherapy or gender has healed. Dr. Mark Persky, a cancer specialist, emphasized "in my review that there is no way to tell whether or not it has caused tumor regression."

In a healthy cell, there is a gene called p53, which can repair DNA, arrest cell growth and trigger cell self-destruction, just like cell damage in cancer. However, in a study by the Chinese Academy of Preventive Medicine, P53 gene damage was found in some cases with asbestos-related cancers, such as mesothelioma.

Gendikina works by activating the p53 gene, which acts as a tumor suppressor but is shut down in a cancer cell because asbestos, chemicals and radiation can be deactivated. Genetic treatment uses the virus as a half-way to transport the p53 gene to cancer cells and causes the p53 gene to reactivate and initiate cancer cell self-destruction (apoptosis).